AU2019242520B2 - Pharmaceutical composition for treatment and/or prevention of cancer - Google Patents

Pharmaceutical composition for treatment and/or prevention of cancer

Info

Publication number
AU2019242520B2
AU2019242520B2 AU2019242520A AU2019242520A AU2019242520B2 AU 2019242520 B2 AU2019242520 B2 AU 2019242520B2 AU 2019242520 A AU2019242520 A AU 2019242520A AU 2019242520 A AU2019242520 A AU 2019242520A AU 2019242520 B2 AU2019242520 B2 AU 2019242520B2
Authority
AU
Australia
Prior art keywords
seq
chain variable
variable region
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019242520A
Other languages
English (en)
Other versions
AU2019242520A1 (en
Inventor
Fumiyoshi Okano
Takanori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of AU2019242520A1 publication Critical patent/AU2019242520A1/en
Application granted granted Critical
Publication of AU2019242520B2 publication Critical patent/AU2019242520B2/en
Priority to AU2026202471A priority Critical patent/AU2026202471A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019242520A 2018-03-30 2019-03-29 Pharmaceutical composition for treatment and/or prevention of cancer Active AU2019242520B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026202471A AU2026202471A1 (en) 2018-03-30 2026-04-01 Pharmaceutical composition for treatment and/or prevention of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-067453 2018-03-30
JP2018067453 2018-03-30
PCT/JP2019/014044 WO2019189780A1 (ja) 2018-03-30 2019-03-29 癌の治療及び／又は予防用医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026202471A Division AU2026202471A1 (en) 2018-03-30 2026-04-01 Pharmaceutical composition for treatment and/or prevention of cancer

Publications (2)

Publication Number Publication Date
AU2019242520A1 AU2019242520A1 (en) 2020-10-29
AU2019242520B2 true AU2019242520B2 (en) 2026-02-26

Family

ID=68062008

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019242520A Active AU2019242520B2 (en) 2018-03-30 2019-03-29 Pharmaceutical composition for treatment and/or prevention of cancer
AU2026202471A Pending AU2026202471A1 (en) 2018-03-30 2026-04-01 Pharmaceutical composition for treatment and/or prevention of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026202471A Pending AU2026202471A1 (en) 2018-03-30 2026-04-01 Pharmaceutical composition for treatment and/or prevention of cancer

Country Status (9)

Country Link
US (1) US20210121562A1 (https=)
EP (1) EP3777888A4 (https=)
JP (1) JP7342701B2 (https=)
CN (1) CN111936164B (https=)
AU (2) AU2019242520B2 (https=)
BR (1) BR112020019935A2 (https=)
CA (1) CA3095719A1 (https=)
MX (1) MX2020009862A (https=)
WO (1) WO2019189780A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911926A2 (pt) * 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
WO2021182574A1 (ja) * 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
KR20220152309A (ko) * 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CA3175277A1 (en) * 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175137A1 (en) * 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4119159A4 (en) * 2020-03-12 2024-03-27 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20250228937A1 (en) * 2021-06-23 2025-07-17 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
MX2023014498A (es) * 2021-06-23 2024-01-25 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
WO2023008461A1 (ja) * 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
KR20240041917A (ko) * 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CN117693363A (zh) * 2021-07-27 2024-03-12 东丽株式会社 用于癌的治疗和/或预防的药品
CA3232439A1 (en) * 2021-09-16 2023-03-23 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN114213534B (zh) * 2022-02-21 2022-06-03 南京佰抗生物科技有限公司 抗人PlGF鼠源单克隆抗体及应用
AU2023334696A1 (en) * 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250053841A (ko) * 2022-08-30 2025-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CN115992142B (zh) * 2022-12-15 2023-10-13 徐州医科大学 与神经保护相关的hsa_circ_0000288及用途
MX2025006330A (es) * 2022-12-23 2025-07-01 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer
KR20240102594A (ko) 2022-12-26 2024-07-03 한국원자력연구원 백금족 원소가 도포된 니켈 스폰지 및 그 제조 방법
WO2024204325A1 (ja) 2023-03-28 2024-10-03 東レ株式会社 細胞膜タンパク質を検出する方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324842A1 (en) * 2008-08-05 2011-05-25 Toray Industries, Inc. Immunity-inducing agent
EP2532367A1 (en) * 2010-02-04 2012-12-12 Toray Industries, Inc. Pharmaceutical agent for treatment and/or prevention of cancer
EP2818481A1 (en) * 2012-02-21 2014-12-31 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP2832366A1 (en) * 2012-03-30 2015-02-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gall bladder cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
US9115200B2 (en) * 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2014303375B2 (en) * 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2015209277B2 (en) 2014-01-22 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
ES2761861T3 (es) * 2015-01-21 2020-05-21 Univ Leland Stanford Junior Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
CN109890417A (zh) * 2016-10-28 2019-06-14 东丽株式会社 癌的治疗和/或预防用药物组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324842A1 (en) * 2008-08-05 2011-05-25 Toray Industries, Inc. Immunity-inducing agent
EP2532367A1 (en) * 2010-02-04 2012-12-12 Toray Industries, Inc. Pharmaceutical agent for treatment and/or prevention of cancer
EP2818481A1 (en) * 2012-02-21 2014-12-31 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP2832366A1 (en) * 2012-03-30 2015-02-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gall bladder cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "History of Changes for Study: NCT03276832, Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma", CLINICALTRIALS.GOV, 20 December 2017 (2017-12-20), XP002804523, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03276832?V_2=View#StudyPageTop> [retrieved on 20211012] *
LIPMAN, N., et al. "Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources", ILAR Journal, Volume 46, Issue 3, 2005, Pages 258-268, https://doi.org/10.1093/ilar.46.3.258 *
SALAZAR LUPE G. ET AL: "Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases : A Phase 2 Clinical Trial", JAMA ONCOLOGY, vol.3, no.7, 2017-07-01, pages 969, [retrieved on 20211012], DOI: 10.1001/jamaoncol.2016.6007 *

Also Published As

Publication number Publication date
AU2026202471A1 (en) 2026-04-23
WO2019189780A1 (ja) 2019-10-03
CN111936164B (zh) 2024-09-17
RU2020135583A (ru) 2022-05-04
CA3095719A1 (en) 2019-10-03
EP3777888A1 (en) 2021-02-17
EP3777888A4 (en) 2021-12-01
AU2019242520A1 (en) 2020-10-29
JPWO2019189780A1 (ja) 2021-02-12
JP7342701B2 (ja) 2023-09-12
BR112020019935A2 (pt) 2021-01-26
US20210121562A1 (en) 2021-04-29
CN111936164A (zh) 2020-11-13
RU2020135583A3 (https=) 2022-05-04
MX2020009862A (es) 2020-10-08
KR20200136935A (ko) 2020-12-08

Similar Documents

Publication Publication Date Title
AU2019242520B2 (en) Pharmaceutical composition for treatment and/or prevention of cancer
JP7797875B2 (ja) 癌の治療及び／又は予防のための医薬品
US20250228937A1 (en) Medicament for treatment and/or prevention of cancer
JP2025181951A (ja) 癌の治療及び／又は予防のための医薬品
JP7715041B2 (ja) 癌の治療及び／又は予防のための医薬品
JP7793986B2 (ja) 癌の治療及び／又は予防のための医薬品
JP7793985B2 (ja) 癌の治療及び／又は予防のための医薬品
EP4578458A1 (en) Medicament for treatment and/or prevention of cancer
US20240325529A1 (en) Medicament for treatment and/or prevention of cancer
EP4578459A1 (en) Pharmaceutical product for treatment and/or prevention of cancer
EP4582101A1 (en) Medicament for treatment and/or prevention of cancer
EP4378476A1 (en) Medicament for treatment and/or prevention of cancer
EP4640235A1 (en) Medicament for treatment and/or prevention of cancer
CA3227703A1 (en) Medicament for treatment and/or prevention of cancer